Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069834 | 1.00 | CYP3A4 (0.46) | CYP3A4CYP2D6CYP11B2CYP11B1CYP1A2 | |
| SCHEMBL9964930 | 0.84 | KCNH2 (0.37) | CYP3A4MAOAMAOB | |
| SCHEMBL9964774 | 0.84 | KCNH2 (0.37) | CYP3A4MAOAMAOB | |
| SCHEMBL14069203 | 0.84 | KCNH2 (0.37) | CYP3A4MAOAMAOB | |
| SCHEMBL13429861 | 0.83 | CYP11B1 (0.51) | CYP3A4CYP11B2CYP11B1CYP1A2CYP17A1 | |
| SCHEMBL9964867 | 0.82 | KCNH2 (0.34) | CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL14069356 | 0.82 | KCNH2 (0.34) | CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL14069246 | 0.82 | MAOA (0.41) | CYP3A4CYP2D6SRD5A1MAOAMAOB | |
| SCHEMBL14069236 | 0.82 | MAOA (0.41) | CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL14069831 | 0.82 | KCNH2 (0.35) | CYP3A4CYP2C9MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | CYP3A4 140/4885CYP2D6 31/4885CYP11B2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.